In eyes with
decreased vision from DME, treatment costs of aflibercept and ranibizumab would need to
decrease by 69 percent and 80 percent, respectively, to reach a cost - effectiveness threshold of $ 100,000 per QALY compared with bevacizumab
during a 10 - year horizon.